HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors

por Spector, Neil, Xia, Wenle, El-Hariry, Iman, Yarden, Yossi, Bacus, Sarah
Publicado 2007

A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis

por Lindzen, Moshit, Carvalho, Silvia, Starr, Alex, Ben-Chetrit, Nir, Pradeep, Chaluvally-Raghavan, Köstler, Wolfgang J., Rabinkov, Aaron, Lavi, Sara, Bacus, Sarah S., Yarden, Yosef
Publicado 2011

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor

por Spector, Neil L., Robertson, Faith C., Bacus, Sarah, Blackwell, Kimberly, Smith, Deborah A., Glenn, Kelli, Cartee, Leanne, Harris, Jennifer, Kimbrough, Carie L., Gittelman, Mark, Avisar, Eli, Beitsch, Peter, Koch, Kevin M.
Publicado 2015

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

por Xia, Wenle, Petricoin, Emanual F, Zhao, Sumin, Liu, Leihua, Osada, Takuya, Cheng, Qing, Wulfkuhle, Julia D, Gwin, William R, Yang, Xiaoyi, Gallagher, Rosa I, Bacus, Sarah, Lyerly, H Kim, Spector, Neil L
Publicado 2013